Literature DB >> 20238102

Increased serum osteopontin is a risk factor for osteoporosis in menopausal women.

I-C Chang1, T-I Chiang, K-T Yeh, H Lee, Y-W Cheng.   

Abstract

SUMMARY: Osteopontin (OPN)-deficient mice are resistant to ovariectomy-induced osteoporosis. Therefore, we hypothesized that women with OPN overexpression may show less resistance to postmenopausal osteoporosis. In this study, we first demonstrated that serum OPN levels could be used as a biomarker for the early diagnosis of osteoporosis in postmenopausal women.
INTRODUCTION: Animal studies indicate that OPN-deficient mice are resistant to ovariectomy-induced osteoporosis.
METHODS: From 2004 to 2006, 124 women over the age of 45 were enrolled in a menopausal group, while another 95 women, from 25 to 45 years of age with regular menstruation, were enrolled into a childbearing age group. The serum concentrations of OPN were calculated using the enzyme-link immunosorbent assay method, and bone mineral densities were determined with dual energy X-ray absorptiometry.
RESULTS: Serum OPN levels had a significant positive correlation with age (menopausal group, p < 0.0001) and a negative correlation with body weight, height, hip bone mineral density, and T-scores in the menopausal group. In contrast, there was a positive correlation with the E2 concentration and height, but there was no significant association with the above variables in the childbearing age group. Additionally, high serum OPN levels (>14.7 ng/ml) was a significant risk factor causing menopausal osteoporosis (odds ratio = 2.96, 95% confidence interval, 1.055-8.345).
CONCLUSION: Serum OPN levels could be used as a biomarker for the early diagnosis of osteoporosis in postmenopausal women.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20238102     DOI: 10.1007/s00198-009-1107-7

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  45 in total

1.  Characterization of perimenopausal bone loss: a prospective study.

Authors:  R Recker; J Lappe; K Davies; R Heaney
Journal:  J Bone Miner Res       Date:  2000-10       Impact factor: 6.741

2.  Interaction of osteopontin with osteoclast integrins.

Authors:  M A Horton; M A Nesbit; M H Helfrich
Journal:  Ann N Y Acad Sci       Date:  1995-04-21       Impact factor: 5.691

3.  Osteopontin is associated with nuclear factor kappaB gene expression during tail-suspension-induced bone loss.

Authors:  Muneaki Ishijima; Yoichi Ezura; Kunikazu Tsuji; Susan R Rittling; Hisashi Kurosawa; David T Denhardt; Mitsuru Emi; Akira Nifuji; Masaki Noda
Journal:  Exp Cell Res       Date:  2006-06-07       Impact factor: 3.905

Review 4.  Osteopontin in urinary stone formation.

Authors:  J R Hoyer; L Otvos; L Urge
Journal:  Ann N Y Acad Sci       Date:  1995-04-21       Impact factor: 5.691

5.  Receptor-ligand interaction between CD44 and osteopontin (Eta-1).

Authors:  G F Weber; S Ashkar; M J Glimcher; H Cantor
Journal:  Science       Date:  1996-01-26       Impact factor: 47.728

6.  Osteopontin deficiency induces parathyroid hormone enhancement of cortical bone formation.

Authors:  Keiichiro Kitahara; Muneaki Ishijima; Susan R Rittling; Kunikazu Tsuji; Hisashi Kurosawa; Akira Nifuji; David T Denhardt; Masaki Noda
Journal:  Endocrinology       Date:  2003-05       Impact factor: 4.736

7.  Osteopontin deficiency and aging on nanomechanics of mouse bone.

Authors:  N Beril Kavukcuoglu; David T Denhardt; Nejat Guzelsu; Adrian B Mann
Journal:  J Biomed Mater Res A       Date:  2007-10       Impact factor: 4.396

8.  Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro.

Authors:  S R Rittling; H N Matsumoto; M D McKee; A Nanci; X R An; K E Novick; A J Kowalski; M Noda; D T Denhardt
Journal:  J Bone Miner Res       Date:  1998-07       Impact factor: 6.741

9.  Plasma osteopontin levels in patients with head and neck cancer and cervix cancer are critically dependent on the choice of ELISA system.

Authors:  Dirk Vordermark; Harun M Said; Astrid Katzer; Thomas Kuhnt; Gabriele Hänsgen; Jürgen Dunst; Michael Flentje; Matthias Bache
Journal:  BMC Cancer       Date:  2006-08-15       Impact factor: 4.430

10.  Bone sialoprotein plays a functional role in bone formation and osteoclastogenesis.

Authors:  Luc Malaval; Ndéyé Marième Wade-Guéye; Maya Boudiffa; Jia Fei; Ralph Zirngibl; Frieda Chen; Norbert Laroche; Jean-Paul Roux; Brigitte Burt-Pichat; François Duboeuf; Georges Boivin; Pierre Jurdic; Marie-Hélène Lafage-Proust; Joëlle Amédée; Laurence Vico; Janet Rossant; Jane E Aubin
Journal:  J Exp Med       Date:  2008-05-05       Impact factor: 14.307

View more
  28 in total

Review 1.  Nonalcoholic fatty liver disease and decreased bone mineral density: is there a link?

Authors:  G Targher; A Lonardo; M Rossini
Journal:  J Endocrinol Invest       Date:  2015-05-24       Impact factor: 4.256

2.  Synthesis of (-)-Astrogorgiadiol.

Authors:  Douglass F Taber; David M Raciti
Journal:  Tetrahedron       Date:  2011-12-30       Impact factor: 2.457

3.  Comparison of pro-inflammatory cytokines and bone metabolism mediators around titanium and zirconia dental implant abutments following a minimum of 6 months of clinical function.

Authors:  Christopher A Barwacz; Kim A Brogden; Clark M Stanford; Deborah V Dawson; Erica N Recker; Derek Blanchette
Journal:  Clin Oral Implants Res       Date:  2014-01-13       Impact factor: 5.977

4.  Osteopontin regulates anabolic effect in human menopausal osteoporosis with intermittent parathyroid hormone treatment.

Authors:  T-I Chiang; I-C Chang; H-S Lee; H Lee; C-H Huang; Y-W Cheng
Journal:  Osteoporos Int       Date:  2010-08-24       Impact factor: 4.507

Review 5.  Bone health in multiple sclerosis.

Authors:  J C Gibson; G D Summers
Journal:  Osteoporos Int       Date:  2011-05-21       Impact factor: 4.507

6.  Serum levels of the bone turnover markers dickkopf-1, sclerostin, osteoprotegerin, osteopontin, osteocalcin and 25-hydroxyvitamin D in Swedish geriatric patients aged 75 years or older with a fresh hip fracture and in healthy controls.

Authors:  P Wanby; R Nobin; S-P Von; L Brudin; M Carlsson
Journal:  J Endocrinol Invest       Date:  2016-02-05       Impact factor: 4.256

7.  Quantitative genetic study of the circulating osteopontin in community-selected families.

Authors:  S Ermakov; A Leonov; S Trofimov; I Malkin; G Livshits
Journal:  Osteoporos Int       Date:  2010-10-22       Impact factor: 4.507

8.  Effects of Administration of Amlodipine and Lacidipine on Inflammation-Induced Bone Loss in the Ovariectomized Rat.

Authors:  Emre Karakus; Zekai Halici; Abdulmecit Albayrak; Yasin Bayir; Elif Demirci; Ali Aydin; Berna Ozturk-Karagoz; Elif Cadirci; Arif Kursat Ayan; Ali Sahin; Deniz Unal
Journal:  Inflammation       Date:  2016-02       Impact factor: 4.092

9.  Osteopontin in bone mineral density of very old Brazilians.

Authors:  Vinícius C Souza; Wladimir M Freitas; Luiz A Quaglia; Simone N Santos; Cláudio Córdova; Andrei C Sposito; Otávio T Nóbrega
Journal:  J Bone Miner Metab       Date:  2013-03-21       Impact factor: 2.626

10.  A study of the link between bone turnover markers and bone mineral density with inflammation and body mass in postmenopausal women with active rheumatoid arthritis.

Authors:  Anna Straburzyńska-Lupa; Alicja Nowak; Wojciech Romanowski; Paweł Korman; Łucja Pilaczyńska-Szcześniak
Journal:  J Bone Miner Metab       Date:  2012-11-28       Impact factor: 2.626

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.